Systemic sclerosis (scleroderma) poses diagnostic and management challenges due to its diverse and often subtle early manifestations. Early skin changes, such as Reynaud’s phenomenon or mild skin tightening, are frequently misinterpreted, leading to delayed diagnosis and missed opportunities for early intervention. If the clinician relies on serologic markers alone, it can lead to false reassurance or misdiagnosis, as these markers are neither universally present nor specific. Systemic manifestations, including pulmonary (such as interstitial lung disease), gastrointestinal, renal and cardiovascular complications (such as pulmonary arterial hypertension), are often under-recognised, contributing significantly to morbidity and mortality. Misdiagnosing any form of scleroderma can delay essential systemic treatments, increasing the risk of irreversible organ damage. Medication side effects and non-adherence further complicate management, while psychosocial challenges, including depression and anxiety, are often overlooked. Comprehensive care requires vigilant screening for early signs, systematic evaluation for organ involvement and personalised, multidisciplinary treatment strategies. By addressing these pitfalls, clinicians can improve early detection, optimise management and enhance the quality of these patients.